Avalo Therapeutics, Inc.

We are a clinical stage biotechnology company fully dedicated to developing IL-1 -based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1 monoclonal antibody ( mAb ) is in a Phase 2 clinical trial for hidradenitis suppurativa ( HS ). We are also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. Our current focus is on completing the Phase 2 ( LOTUS ) trial evaluating abdakibart (AVTX-009) in HS, preparing for the anticipated topline data readout in the second quarter of 2026, and planning for our Phase 3 trial(s). Our Strategy Our strategy for increasing stockholder value includes: Advancing our pipeline through development to regulatory approval notably and in the near term, by completing our Phase 2 LOTUS trial in HS, preparing to initiate our pivotal trial(s) pending the readout of the Phase 2 LOTUS trial results and considering further indication expansion for abdakibart (AVTX-009); Acquiring or in-licensing rights to and/or developing targeted, complementary differentiated preclinical and clinical stage compounds that treat immune-mediated inflammatory disease; and Opportunistically out-licensing rights to compounds, indications or geographies. Pipeline - Overview, Competition, and Intellectual Property We are advancing a pipeline that emphasizes a high-value and potentially best-in-class and best-in-disease biologics for immune mediated inflammatory diseases.